Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

ed merger transaction with Immune Pharmaceuticals; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for AmiKet™ or crolibulin™ will not be successful; the risk that AmiKet™, Azixa® or crolibulin™ will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that Ceplene® will not receive regulatory approval or marketing authorization in the United States or Canada; the risk that Ceplene® will not achieve significant commercial success; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securit
'/>"/>
SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Peter Walter ... Biomedical Science for his pioneering work on how proteins ... components of a regulatory mechanism that cells use to ... Dr. Walter is a professor of biochemistry at the ... groundwork for treating a range of human diseases related ...
(Date:3/26/2015)... March 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... on providing advanced testing solutions for the detection ... for the three months and full year ended ... Financial Results:Revenue for the quarter ended December 31, ... the fourth quarter of 2013 and $1.5 million ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... Advanced Scientific Knowledge, Highlight Most Recent ... ... ArcMesa Educators, an accredited,provider of continuing education courses, is proud ... by years of scientific,experience and advanced degrees in molecular biology, structural ...
... AUSTIN, Texas, Sept. 27 Luminex Corporation,(Nasdaq: ... at the,Biotechnology Industry Organization Investor Forum to be ... investor presentation by Patrick J. Balthrop, president and ... officer, will,begin at 9:30 a.m. Pacific time; 12:30 ...
... GENZ ) confirmed today that it will not change ... $5.60 in cash per,outstanding common share as set forth ... owns approximately 22 percent of the,outstanding shares of Bioenvision ... its preferred stock that carry a unique set of,rights ...
Cached Biology Technology:ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 2ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 3Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 3
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
(Date:3/17/2015)... March 17, 2015  MecklerMedia Corporation (OTCQX: MECK) ... for service robots ever held in ... on May 11-13, 2015 at the Javits Convention ... the event include: Acorn Product Development; Axis NJ; ... Kinova Robotics; Littler; NewBotic Corporation; Neya Systems LLC; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... is a severely debilitating psychiatric disease that is thought ... nervous system; however, major breakthroughs linking its genetics to ... PhD assistant professor of Pediatrics at Northwestern University,s Feinberg ... Molecular Genetics Program of Children,s Memorial Research Center studies ...
... A common variation of the gene involved in ... linked to problem behaviors in adults with developmental and ... published in the July 2009 issue of the ... are available online at http://tinyurl.com/mw8baj . "Problem ...
... only a few millimeters up to a few centimeters in ... research, because they possess the extraordinary ability to regenerate lost ... even grow an entirely new worm out of minute amputated ... Berlin, Germany together with researchers in the US and Canada ...
Cached Biology News:A genetic basis for schizophrenia 2Genetic marker linked to problem behaviors in adults with developmental disabilities 2International research team seeks to unravel flatworm regeneration 2
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
... Rabbit polyclonal to HDAC4 - ChIP ... the class II mammalian histone deacetylases, which ... C-terminal sequence is highly similar to the ... other deacetylases, shuttles between the nucleus and ...
Biology Products: